Portfolio

NovaMedica aims to provide doctors and patients with access to the most innovative and effective pharmaceutical products. The NovaMedica portfolio is formed from drugs developed and registered within our own R&D-program (these drugs are manufactored by the R&D-Center NovaMedica Innotech in Moscow) as well as from products from our partners.

Key development area of NovaMedica’s product portfolio is NEUROLOGY/CNS, an area in which the search for new effective solutions has extraordinary social importance.​ This segment of our portfolio currently includes the following products:


Seroquel® – a modern the 2nd generation antipsychotic for:

- Contradictory long-term therapy in patients with a chronic course of schizophrenia;

- Treatment of patients with newly diagnosed schizophrenia;

- Correction of negative symptoms and cognitive deficit in patients with schizophrenia;

- Therapy of schizophrenia patients with therapeutic resistance to traditional neuroleptics.

Seroquel® Prolong – is an antipsychotic (neuroleptic) for the treatment of:

- Schizophrenia, including relapse prevention in stable patients;

- Bipolar disorders, including: moderate and severe manic episodes in the structure of bipolar disorder, severe episodes of depression in the structure of bipolar disorder, prevention of relapse of bipolar disorders in patients with prior effective quetiapine therapy of manic or depressive episodes in the structure of bipolar disorder.

Mioreol® - innovative drug based on donepezil and memantine molecules which are most commonly used in the treatment of Alzheimer disease for patients with moderate and severe forms of this disease.

Relonova® is an innovative drug based on the rizatriptan molecule for the relief of a migraine attack (headache and associated symptoms). Relonova® is a proprietary development of NovaMedica and is produced in Russia on a full cycle basis.

Levroso® Long is an innovative combined drug (diphenhydramine + sustained release melatonin) for the treatment of insomnia, which is a proprietary development of NovaMedica and is produced in Russia.

Difendum – diclofenac potassium 12,5 mg and 25 mg, locally produced in Russia, in soft gelatin capsules for pain syndrome treatment, especially head ache.Difendum – diclofenac potassium 12,5 mg and 25 mg, locally produced in Russia, in soft gelatin capsules for pain syndrome treatment, especially head ache.

All products passed Clinical Trials and registered in Russia.

PRODUCTS HAVE CONTRAINDICATIONS. PLEASE CONSULT A SPECIALIST BEFORE USE

Our news

All news

Media Center

Read more